Equities

Cyfuse Biomedical KK

4892:TYO

Cyfuse Biomedical KK

Actions
  • Price (JPY)463.00
  • Today's Change-21.00 / -4.34%
  • Shares traded51.60k
  • 1 Year change-43.19%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,8744,4372,413
Total Receivables, Net507058
Total Inventory464062
Prepaid expenses171826
Other current assets, total0.440.110.22
Total current assets3,9874,5652,559
Property, plant & equipment, net17018927
Goodwill, net------
Intangibles, net4.375.484.81
Long term investments0.010.010.01
Note receivable - long term------
Other long term assets535556
Total assets4,2154,8152,646
LIABILITIES
Accounts payable1.283.208.28
Accrued expenses202637
Notes payable/short-term debt550467129
Current portion long-term debt/capital leases187880
Other current liabilities, total77108132
Total current liabilities666683386
Total long term debt345363360
Total debt913908569
Deferred income tax------
Minority interest------
Other liabilities, total0.00--0.00
Total liabilities1,0111,046746
SHAREHOLDERS EQUITY
Common stock1,2831,272100
Additional paid-in capital3,9053,8942,722
Retained earnings (accumulated deficit)(1985)(1396)(922)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0.00
Total equity3,2033,7701,900
Total liabilities & shareholders' equity4,2154,8152,646
Total common shares outstanding7.897.777.17
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.